1,193 results on '"Foley, John F"'
Search Results
2. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
3. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
4. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
5. NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system.
6. In Science Journals
7. Nanobody pharmacology
8. Taking down tumors takes atypical integrins
9. Polarizing itch
10. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
11. Poachers turned gamekeepers in T cells
12. In Science Journals
13. In Science Journals
14. Systemic inflammation from the brain
15. Characterization of Subsets of CD4 + Memory T Cells Reveals Early Branched Pathways of T Cell Differentiation in Humans
16. Stress granules plug holes
17. In Science Journals
18. Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis
19. In Science Journals
20. Restraining neuroinflammation in Alzheimer’s disease
21. In Science Journals
22. In Science Journals
23. An ion channel’s high five
24. Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
25. In Science Journals
26. Bypassing ACE2
27. Pain Management in Multiple Sclerosis
28. Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis.
29. Stressing the gut-brain axis
30. In Science Journals
31. Extended-interval dosing of natalizumab in NOVA – Authors' reply
32. Dopamine suppresses ILC2s
33. A check on the immunological synapse
34. CMTM4 makes IL-17 signaling more complex
35. In Science Journals
36. In Science Journals
37. Modulation by macrocyclic peptides
38. Association between Serum Biomarker Profile and Real-World Evidence of Disability in Multiple Sclerosis
39. Telomeres to go
40. The β 2 AR gets SNOed
41. Taking the STING out of aging?
42. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
43. Editorial expression of concern
44. In Science Journals
45. An Insider's View
46. A twist in β-arrestin’s tail
47. In Science Journals
48. Shining a light on rhodopsin signaling
49. Obesity and antitumor immunity
50. In Science Journals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.